Informations générales (source: ClinicalTrials.gov)
Efficacy of Ericksonian Hypnosis in the Management of Chronic Pain Related to Parkinson's Disease (DOLHYP-PARK-1)
Interventional
N/A
University Hospital, Lille (Voir sur ClinicalTrials)
août 2020
août 2024
03 août 2024
This study evaluates the efficacity of Erickson hypnosis in the treatment of chronic pain
in patients with Parkinson's disease. Half of participants will follow a 2-month Erickson
hypnosis protocole, while the other half will benefit from the usual care.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Chu Cote de Nacre - Caen - France | Contact (sur clinicalTrials) | ||||
| Hôpital Roger Salengro, CHRU de Lille - 59800 - Lille - France | Kathy Dujardin, PhD | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Hopital Charles Nicolle Chu Rouen - Rouen - France | Contact (sur clinicalTrials) | ||||
| Hopital Purpan Chu Toulouse - 31300 - Toulouse - France | Contact (sur clinicalTrials) | ||||
Critères
Tous
Inclusion Criteria:
- Men or women
- 18 to 80 years old
- idiopathic Parkinson's disease
- without neurological co-morbidity
- Suffering from chronic pain (for at least 3 months), related to Parkinson's disease
- Having a pain intensity of at least 30 mm on the VAS (average intensity over the
previous week) for Parkinson's disease-related pain
- antiparkinsonian, analgesic and psychotropic treatments stable for 1-month
- having a health insurance
- signed informed consent form
- Men or women
- 18 to 80 years old
- idiopathic Parkinson's disease
- without neurological co-morbidity
- Suffering from chronic pain (for at least 3 months), related to Parkinson's disease
- Having a pain intensity of at least 30 mm on the VAS (average intensity over the
previous week) for Parkinson's disease-related pain
- antiparkinsonian, analgesic and psychotropic treatments stable for 1-month
- having a health insurance
- signed informed consent form
- Patient with a neurological condition other than Parkinson's disease or with an
atypical Parkinson's syndrome
- Early untreated patient
- Patient with acute intercurrent pain
- Patient whose pain is mainly attributable to another pathology (rheumatoid
arthritis, spondyloarthritis ankylosing, diabetic neuropathy, cancer, etc.)
- Patient with cognitive impairment objectified by a score at the Montreal Cognitive
Assessment (MoCA) <24
- Patient with hallucinations and/or psychosis (MDS-UPDRS 1.2> 1)
- Patient with a apathy (MDS-UPDRS 1.5> 1)
- Patient with disabling dyskinesia (MDS-UPDRS) 4.1 AND 4.2> 1)
- Patient under the protection of adults
- Pregnant or lactating woman